AI-generated summary
The authors retrospectively reviewed 76 patients with long-standing neurosensory disturbances after trigeminal nerve injury who received GaAlAs diode laser photobiomodulation. They report that 59% felt subjectively improved, but found no statistically significant effect compared with patients who did not respond. Without a control group, the authors caution that placebo effects and spontaneous recovery may have influenced results.
- Participants
- 76
- Who or what was studied
- Patients with post-traumatic trigeminal neuropathy and neurosensory symptoms lasting more than 3 months, treated between 2007 and 2018
- Limits stated in the abstract
- Retrospective design, no control group, heterogeneity in etiology, nerve injury type and timing of treatment, and subjective outcome measures susceptible to placebo effects.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Post-traumatic trigeminal neuropathy (PTTN) can significantly affect quality of life (QoL) due to pain and sensory disturbances. This study aimed to evaluate the effectiveness of photobiomodulation (PBM) therapy in patients with long-standing neurosensory disturbances associated with PTTN, using a protocol implemented at our department.
Methods
A retrospective analysis was conducted on 76 cases treated between 2007 and 2018. All had neurosensory symptoms lasting more than 3 months. Data were collected from the clinical records, a structured questionnaire, and Visual Analogue Scale (VAS) scores. PBM therapy was administered using a GaAlAs diode laser. Patients were stratified based on time from injury to treatment (< 12 months vs. > 12 months).
Results
Following PBM therapy, 59% of patients reported subjective improvement (30% extensive, 29% slight), while 38% reported no change and 2.6% noted slight deterioration. No statistically significant differences were observed between the groups that responded to PBM therapy and those that did not. Similarly, treatment outcomes showed no significant association with gender, etiology, affected nerve, time to treatment, or number of sessions.
Conclusions
The current study did not demonstrate a statistically significant effect of PBM therapy in patients with neurosensory disturbances associated with PTTN under the applied treatment protocol. Due to the retrospective design, the absence of a control group, and the heterogeneity in patients, etiology, nerve injury types, and timing of treatment, we hypothesize that variables such as laser dosage, session intervals, and application technique may have influenced the lack of observed therapeutic benefit. Subjective improvements must be interpreted cautiously due to potential placebo effects and spontaneous nerve recovery. These findings underscore the need for standardized PBM protocols and well-designed randomized controlled trials (RCTs) to validate treatment efficacy in trigeminal nerve injuries.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Visual analogue scale, Laser, Control group, Heterogeneity, Neuropathy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.